Nabiximols (THC/CBD Oromucosal Spray, Sativex®) in Clinical Practice - Results of a Multicenter, Non-Interventional Study (MOVE 2) in Patients with Multiple Sclerosis Spasticity

Publisher： Karger

E-ISSN： 1421-9913|71|5-6|271-279

ISSN： 0014-3022

Source： European Neurology, Vol.71, Iss.5-6, 2014-02, pp. : 271-279

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Effectiveness and Tolerability of THC/CBD Oromucosal Spray for Multiple Sclerosis Spasticity in Italy: First Data from a Large Observational Study

By  

European Neurology, Vol. 74, Iss. 3-4, 2015-11 ,pp. : 178-185

Karger

Access to resources Recommend Favorite

Influence of Previous Failed Antispasticity Therapy on the Efficacy and Tolerability of THC:CBD Oromucosal Spray for Multiple Sclerosis Spasticity

By  

European Neurology, Vol. 75, Iss. 5-6, 2016-05 ,pp. : 236-243

Karger

Access to resources Recommend Favorite

THC:CBD Spray and MS Spasticity Symptoms: Data from Latest Studies

By  

European Neurology, Vol. 71, Iss. 1, 2014-01 ,pp. : 4-9

Karger

Access to resources Recommend Favorite

Tetrahydrocannabinol:Cannabidiol Oromucosal Spray for Multiple Sclerosis-Related Resistant Spasticity in Daily Practice

By  

European Neurology, Vol. 76, Iss. 5-6, 2016-10 ,pp. : 216-226

Karger

Access to resources Recommend Favorite

Swiss Analysis of Multiple Sclerosis: A Multicenter, Non-Interventional, Retrospective Cohort Study of Disease-Modifying Therapies

By  

European Neurology, Vol. 70, Iss. 1-2, 2013-05 ,pp. : 35-41

Karger

Access to resources Recommend Favorite